WO2006085075A3 - Colonic delivery of active agents - Google Patents

Colonic delivery of active agents Download PDF

Info

Publication number
WO2006085075A3
WO2006085075A3 PCT/GB2006/000448 GB2006000448W WO2006085075A3 WO 2006085075 A3 WO2006085075 A3 WO 2006085075A3 GB 2006000448 W GB2006000448 W GB 2006000448W WO 2006085075 A3 WO2006085075 A3 WO 2006085075A3
Authority
WO
WIPO (PCT)
Prior art keywords
colon
polyethyleneimine
pectin
beads
amount
Prior art date
Application number
PCT/GB2006/000448
Other languages
French (fr)
Other versions
WO2006085075A2 (en
Inventor
Elias Fattal
Antoine Andremont
Patrick Couvreur
Sandrine Bourgeois
Original Assignee
Da Volterra
Centre Nat Rech Scient
Stevens Ian Edward
Elias Fattal
Antoine Andremont
Patrick Couvreur
Sandrine Bourgeois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Da Volterra, Centre Nat Rech Scient, Stevens Ian Edward, Elias Fattal, Antoine Andremont, Patrick Couvreur, Sandrine Bourgeois filed Critical Da Volterra
Priority to EP06709686A priority Critical patent/EP1845948A2/en
Priority to AU2006211996A priority patent/AU2006211996A1/en
Priority to JP2007553714A priority patent/JP2008529996A/en
Priority to CA002595526A priority patent/CA2595526A1/en
Priority to BRPI0606943-6A priority patent/BRPI0606943A2/en
Priority to US11/628,832 priority patent/US20080317666A1/en
Publication of WO2006085075A2 publication Critical patent/WO2006085075A2/en
Publication of WO2006085075A3 publication Critical patent/WO2006085075A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Abstract

Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Chrohn's Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink density of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amount of time such that a substantial amount of the active ingredients can be administered directly to the colon. Advantageously, the amount of polyethyleneimine is sufficient to allow a substantial portion of the pectin beads to pass through the gastrointestinal tract to the colon without releasing the active agent, and is also sufficient such that the pectin beads are sufficiently degraded in the colon to release an effective amount of the active agent.
PCT/GB2006/000448 2005-02-09 2006-02-09 Colonic delivery of active agents WO2006085075A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06709686A EP1845948A2 (en) 2005-02-09 2006-02-09 Colonic delivery of active agents
AU2006211996A AU2006211996A1 (en) 2005-02-09 2006-02-09 Colonic delivery of active agents
JP2007553714A JP2008529996A (en) 2005-02-09 2006-02-09 Intestinal delivery of active factors
CA002595526A CA2595526A1 (en) 2005-02-09 2006-02-09 Colonic delivery of active agents
BRPI0606943-6A BRPI0606943A2 (en) 2005-02-09 2006-02-09 delivery of active agents to the colon
US11/628,832 US20080317666A1 (en) 2005-02-09 2006-02-09 Colonic Delivery of Active Agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65134205P 2005-02-09 2005-02-09
US60/651,342 2005-02-09

Publications (2)

Publication Number Publication Date
WO2006085075A2 WO2006085075A2 (en) 2006-08-17
WO2006085075A3 true WO2006085075A3 (en) 2007-08-30

Family

ID=36793399

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000448 WO2006085075A2 (en) 2005-02-09 2006-02-09 Colonic delivery of active agents

Country Status (8)

Country Link
US (1) US20080317666A1 (en)
EP (1) EP1845948A2 (en)
JP (1) JP2008529996A (en)
CN (1) CN101128187A (en)
AU (1) AU2006211996A1 (en)
BR (1) BRPI0606943A2 (en)
CA (1) CA2595526A1 (en)
WO (1) WO2006085075A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US8916182B2 (en) * 2006-11-28 2014-12-23 Universite De Namur Composition comprising oligogalacturonans and polycationic saccharides
WO2009040020A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Amylin as a therapeutic agent
JP2010538994A (en) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of BFGF1-24 and optionally (ARG8) vasopressin, for example to treat Streptococcus pneumoniae infection
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
ZA200903858B (en) * 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
JP5504666B2 (en) * 2009-03-25 2014-05-28 ニプロ株式会社 PHARMACEUTICAL COMPOSITION, PROCESS FOR PRODUCING THE SAME AND SUSTAINED RELEASE BASE
US8852645B2 (en) 2009-11-19 2014-10-07 The Board Of Trustees Of The University Of Illinois Self-assembled toroidal-spiral particles and manufacture and uses thereof
CZ302789B6 (en) * 2009-11-25 2011-11-09 Zentiva, K. S. Method of increasing solubility of pharmaceutically active compounds and targeted (controlled) transport thereof into intestine
FR3027307B1 (en) * 2014-10-16 2016-11-04 Azurrx Sas HYBRID PROTEIN MOLECULE CAPABLE OF INHIBITING AT LEAST ONE ANTIBIOTIC AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
CN108289894A (en) 2015-09-29 2018-07-17 前药扩展私人有限公司 New formulation and therapy
US10940113B2 (en) * 2017-02-24 2021-03-09 Medical And Pharmaceutical Industry Technology And Development Center Pharmaceutical composition for colon targeting, method for treating a colon-related disease using the same and preparation method thereof
CA3106429A1 (en) * 2018-08-05 2020-02-13 Da Volterra Method for improving anticancer agent efficacy
CN113730374B (en) * 2021-08-05 2023-03-24 中新国际联合研究院 Sugar beet pectin-based oral sustained-release gel beads and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843301A1 (en) * 2002-08-09 2004-02-13 Centre Nat Rech Scient Orally administrable multiparticular formulation for intestinal delivery of active agents, comprises pectin granules in the form of a cationic salt containing the active agent, where the pectin is crosslinked with a cationic polymer
WO2004016248A2 (en) * 2002-08-09 2004-02-26 Centre National De La Recherche Scientifique (Cnrs) Galenic formulation for colon targeted delivery of active principles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
FR2608456B1 (en) * 1986-12-18 1993-06-18 Mero Rousselot Satia MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM
DK0454044T3 (en) * 1990-04-25 1996-04-22 Hoechst Ag Pharmacological preparation containing polyelectrolyte complexes in microparticle form and at least one active substance
FI920206A0 (en) * 1992-01-17 1992-01-17 Pekka Untamo Heino MEDICINSK ANVAENDNING, MEDICINSKT FOERFARANDE OCH PREPARAT.
DE69726446T2 (en) * 1996-10-09 2004-08-26 Givaudan S.A. METHOD FOR PRODUCING A PEARL-BASED FOOD ADDITIVE
US6531152B1 (en) * 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
IL130303A0 (en) * 1999-06-03 2000-06-01 M G Novobiotech Ltd A bacterial strain processed plant extracts and probiotic compositions for human and veterinary use
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2843301A1 (en) * 2002-08-09 2004-02-13 Centre Nat Rech Scient Orally administrable multiparticular formulation for intestinal delivery of active agents, comprises pectin granules in the form of a cationic salt containing the active agent, where the pectin is crosslinked with a cationic polymer
WO2004016248A2 (en) * 2002-08-09 2004-02-26 Centre National De La Recherche Scientifique (Cnrs) Galenic formulation for colon targeted delivery of active principles

Also Published As

Publication number Publication date
US20080317666A1 (en) 2008-12-25
CA2595526A1 (en) 2006-08-17
CN101128187A (en) 2008-02-20
BRPI0606943A2 (en) 2009-07-28
AU2006211996A1 (en) 2006-08-17
WO2006085075A2 (en) 2006-08-17
EP1845948A2 (en) 2007-10-24
JP2008529996A (en) 2008-08-07

Similar Documents

Publication Publication Date Title
WO2006085075A3 (en) Colonic delivery of active agents
CN102869351B (en) Formulations for oral delivery of adsorbents in the gut
Park et al. Randomised clinical trial: comparative study of 10‐day sequential therapy with 7‐day standard triple therapy for Helicobacter pylori infection in naïve patients
CA2415643A1 (en) Pharmaceutical composition for oral use with improved absorption
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
NZ728442A (en) Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
WO2006124698A3 (en) Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
EA200401216A1 (en) DOSED FORMS OF AZITROMYCIN WITH REDUCED SIDE EFFECTS
ES2744406T3 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
WO2009037264A3 (en) Colonic delivery of antimicrobial agents
WO2002040702A3 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
CA2304948A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease
WO2005107773A3 (en) Solid dosage form of wetted heparin
ES2336588T3 (en) PHARMACEUTICAL FORMS OF QUICK RELEASE FOR ANTIBIOTICS.
CN1271281A (en) Medicamenet formulation with a controlled release of an active agent
Niranjan et al. Effect of guar gum and xanthan gum compression coating on release studies of metronidazole in human fecal media for colon targeted drug delivery systems
DK0876142T3 (en) Topical administration of drugs to the lower gastrointestinal tract
Gupta et al. Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation
CA2831650A1 (en) Medical products for use in conditions related to microbial infections in the upper aerodigestive tract
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
Aslani et al. Formulation, characterization and physicochemical evaluation of amoxicillin effervescent tablets
Kurian et al. Recent advances of metronidazole-A review.
CA2330256A1 (en) Treatment of inflammatory bowel disease
Sideris et al. Salvage surgery for anal canal carcinomas
File Jr The development of pharmacokinetically enhanced amoxicillin/clavulanate for the management of respiratory tract infections in adults

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2006211996

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2595526

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007553714

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006709686

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006211996

Country of ref document: AU

Date of ref document: 20060209

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006211996

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3118/KOLNP/2007

Country of ref document: IN

Ref document number: 200680005835.X

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006709686

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11628832

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0606943

Country of ref document: BR

Kind code of ref document: A2